^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serotonin reuptake inhibitor

    Related drugs:
    18h
    P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Apr 2026
    Enrollment closed • Trial completion date
    5d
    Exploring the intervention mechanism of modified Danggui buxue decoction on neuroinflammation in CIPN model mice based on transcriptomics and network pharmacology (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    Except for the blank control group, the remaining 48 mice underwent ectopic transplantation of gastric cancer cells into the axilla and were randomly divided into four groups (n=12 per group): the gastric cancer group, the CIPN model group, the modified Danggui buxue decoction group, and Duloxetine group. Conclusion Modified Danggui buxue decoction may ameliorate pathological damage and pain symptoms in the dorsal root ganglia of a mouse model of oxaliplatin-induced peripheral neurotoxicity following gastric cancer chemotherapy. The mechanism is likely associated with the inhibition of the NF-κB signaling pathway in the dorsal root ganglia and the down regulation of ATM, NF-κB, CCL21, TNF-α, IL-1β, and IL-6 expression.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • CCL21 (C-C Motif Chemokine Ligand 21) • IL1B (Interleukin 1, beta)
    |
    oxaliplatin
    7d
    CAPNEUCHIM: Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy (clinicaltrials.gov)
    P3, N=274, Recruiting, Institut Cancerologie de l'Ouest | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028
    Trial completion date • Trial primary completion date
    8d
    RCTVM: Comparison of Amitriptyline to Lifestyle Modification as Intervention for Vestibular Migraine (clinicaltrials.gov)
    P1, N=0, Withdrawn, Vanderbilt University Medical Center | N=100 --> 0 | Enrolling by invitation --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    amitriptyline
    12d
    Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Haydarpasa Numune Training and Research Hospital
    New trial
    13d
    Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy. (PubMed, J Pharm Pharmacol)
    Sex is a crucial biological variable in CIPN, influencing drug efficacy through sex-specific neuroimmune mechanisms and hormonal regulation. These findings underscore the necessity of incorporating sex as a key variable in analgesic development and clinical practice to achieve personalized pain management in CIPN patients.
    Review • Journal
    |
    TLR9 (Toll Like Receptor 9) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    14d
    A Randomized, open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy - A strategy trial (2024-511008-17-00)
    P4, N=110, Completed, Leids Universitair Medisch Centrum (LUMC) | Not yet recruiting --> Completed
    Trial completion • Head-to-Head
    14d
    Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (clinicaltrials.gov)
    P4, N=93, Recruiting, Iuliu Hatieganu University of Medicine and Pharmacy | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    NEFOPAIN kinet: Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology (clinicaltrials.gov)
    P4, N=24, Not yet recruiting, University Hospital, Rouen
    New P4 trial
    16d
    Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects (clinicaltrials.gov)
    P1, N=44, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial
    21d
    CHDR2501: Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone) (2025-522389-66-00)
    P1, N=24, Completed, Centre for Human Drug Research | Recruiting --> Completed
    Trial completion
    21d
    Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT (clinicaltrials.gov)
    P4, N=64, Recruiting, University of Miami | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial completion date • Trial primary completion date